Cargando…
The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli aft...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634941/ https://www.ncbi.nlm.nih.gov/pubmed/37961139 http://dx.doi.org/10.1101/2023.10.30.564761 |
_version_ | 1785146264913969152 |
---|---|
author | Gil-Gil, Teresa Berryhill, Brandon A. Manuel, Joshua A. Smith, Andrew P. McCall, Ingrid C. Baquero, Fernando Levin, Bruce R. |
author_facet | Gil-Gil, Teresa Berryhill, Brandon A. Manuel, Joshua A. Smith, Andrew P. McCall, Ingrid C. Baquero, Fernando Levin, Bruce R. |
author_sort | Gil-Gil, Teresa |
collection | PubMed |
description | Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli after exposure to two ribosome-targeting bacteriostatic antibiotics, chloramphenicol and azithromycin, for thirty days. The results of our experiments provide evidence that bacteria exposed to these drugs replicate, evolve, and generate a sub-population of small colony variants (SCVs) which are resistant to multiple drugs. These SCVs contribute to the evolution of heteroresistance and rapidly revert to a susceptible state once the antibiotic is removed. Stated another way, exposure to bacteriostatic drugs selects for the evolution of heteroresistance in populations previously lacking this trait. More generally, our results question the definition of bacteriostasis as populations exposed to bacteriostatic drugs are replicating despite the lack of net growth. |
format | Online Article Text |
id | pubmed-10634941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-106349412023-11-13 The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics Gil-Gil, Teresa Berryhill, Brandon A. Manuel, Joshua A. Smith, Andrew P. McCall, Ingrid C. Baquero, Fernando Levin, Bruce R. bioRxiv Article Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli after exposure to two ribosome-targeting bacteriostatic antibiotics, chloramphenicol and azithromycin, for thirty days. The results of our experiments provide evidence that bacteria exposed to these drugs replicate, evolve, and generate a sub-population of small colony variants (SCVs) which are resistant to multiple drugs. These SCVs contribute to the evolution of heteroresistance and rapidly revert to a susceptible state once the antibiotic is removed. Stated another way, exposure to bacteriostatic drugs selects for the evolution of heteroresistance in populations previously lacking this trait. More generally, our results question the definition of bacteriostasis as populations exposed to bacteriostatic drugs are replicating despite the lack of net growth. Cold Spring Harbor Laboratory 2023-10-30 /pmc/articles/PMC10634941/ /pubmed/37961139 http://dx.doi.org/10.1101/2023.10.30.564761 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Gil-Gil, Teresa Berryhill, Brandon A. Manuel, Joshua A. Smith, Andrew P. McCall, Ingrid C. Baquero, Fernando Levin, Bruce R. The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title | The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title_full | The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title_fullStr | The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title_full_unstemmed | The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title_short | The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics |
title_sort | evolution of heteroresistance via small colony variants in escherichia coli following long term exposure to bacteriostatic antibiotics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634941/ https://www.ncbi.nlm.nih.gov/pubmed/37961139 http://dx.doi.org/10.1101/2023.10.30.564761 |
work_keys_str_mv | AT gilgilteresa theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT berryhillbrandona theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT manueljoshuaa theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT smithandrewp theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT mccallingridc theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT baquerofernando theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT levinbrucer theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT gilgilteresa evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT berryhillbrandona evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT manueljoshuaa evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT smithandrewp evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT mccallingridc evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT baquerofernando evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics AT levinbrucer evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics |